Categories Earnings, Health Care

Onconova Therapeutics cuts down losses in 2018

Onconova Therapeutics (ONTX), a Phase 3 biopharmaceutical company that focuses on developing cancer drugs, Tuesday posted a narrowed loss in fiscal 2018 helped by higher revenues and cost optimization meThe annual.

Annual loss narrowed to $20.4 million, or $4.99 per share, compared to $24 million, or $40.15 per share in fiscal 2017.

Image for representation (Photo by Drew Hays on Unsplash)

Revenue jumped 56% to $1.2 million during the year, driven by collaboration agreements executed during the first half of 2018. Research and development expenses were $16.9 million for the year ended December 31, 2018, and $19.1 million for the comparable period in 2017.

ONTX shares ended its last trading session down 3.05% on Monday. The stock has declined 71% in the trailing 52 weeks, though it has bounced back this year.

READ: WHAT IS NASH AND WHICH BIOTECH FIRMS ARE VYING FOR THE FIRST-MOVER STATUS

CEO Steven M. Fruchtman said, “As we move through 2019, we anticipate continued progress across the Company, including recruiting for our Phase 3 IV rigosertib trial in second-line higher-risk MDS (HR-MDS) patients and advancing oral rigosertib in combination with azacitidine toward a pivotal phase 3 trial in first-line HR-MDS patients.”

The Pennsylvania-based firm on Monday said it had surpassed the 75% enrollment milestone in its pivotal Phase 3 trial of rigosertib for the potential treatment of high-risk myelodysplastic syndromes (HR-MDS), a study known as INSPIRE.

Full enrolment of 360 patients is anticipated in the second half of 2019.

 

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Cost reduction has become a priority for FedEx (FDX) after a challenging quarter

Shares of FedEx Corporation (NYSE: FDX) were up 1% on Tuesday. The stock has dropped 44% year-to-date and 34% over the past 12 months. The company delivered mixed results for

Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know

After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered the stock market. On the heels of AIG

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top